Audit: QRS - Bergamot Oil for Health & Longevity
Audit conducted on 17/08/2026 05:55 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: at-a-glance vs Conclusion, protocol cells vs Therapeutic Protocol, time cells vs Practical Considerations, benefit/risk tiers vs the ER headings, gates vs Key Interactions & Contraindications, and all 8 monitoring rows + cadence + 6 qualitative items vs Monitoring Protocol & Defining Success. No unsupported statement found. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No cautious empty-state phrasing in the ER is carried into a QRS field; where the ER hedges (e.g. speculative tiers), the QRS keeps the item in the Speculative tier rather than promoting it. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy/lactation stays in the STOP gate (line 565), not in Key Interactions; the CYP3A4 ingestion contraindication keeps “Intended ingestion” scoping (lines 561–562). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER “Populations who should avoid Bergamot Oil” list, Key Interactions from the ER interaction bullets, risks from Potential Risks & Side Effects headings. No Benefit-Modifying Factors or Risk-Modifying Factors content appears in the gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, expert names or brands in the QRS. The study descriptors in the Monitoring “Why” column (“the schoolteacher aromatherapy study”, “the postmenopausal trial”, “the pre-surgical bergamot trial”, “the bergamot vapour trial”) are copied verbatim from the ER biomarker table. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution appears that is not already in the ER table it was drawn from. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Same measured, non-promotional register as the ER; hazard framing (“avoidable with care about sun exposure”) mirrors the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Tiered benefits/risks, concrete dose and timing figures, explicit monitoring targets. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as what trials used and measured, not as orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or second-person constructions; cadence line uses impersonal nominal phrasing (“Baseline over two weeks before starting; … whole protocol reassessed every 6–12 months”). |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, or “should” in the document body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No “you”/”your” anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained (CYP3A4 substrate, oxidized linalool, Fitzpatrick skin type I) are all load-bearing decision terms carried from the ER; nothing is jargon for its own sake. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier entries are stripped to key facts; no mechanism or study detail carried into any card. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no second-person pronouns or imperatives. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Contents (8-marker monitoring panel, salivary cortisol and overnight RMSSD, patch testing) assume a proactive self-quantifying reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Two-week baseline, weekly-then-monthly re-rating and photopatch testing are all retained rather than simplified away. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No general-consumer simplification; full contraindication and interaction detail retained. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance names the modest short-term signal and the single avoidable hazard, matching the ER’s own weighting. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging”; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal register throughout (“phototoxic skin reaction”, “allergic contact dermatitis”, “mucosal irritation”); the plain wording in At-A-Glance is required by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present verbatim (lines 444, 484, 528, 552, 570, 595, 617, 621–623, 741) with unchanged tier labels in both Benefits and Risks. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variable names present; the repeatable marker_#_* and qualitative_item_# rows are expanded to marker_1–8 and qualitative_item_1–6 as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows only variable regions changed; <span website="evidence_review">, <span website="audit"> and <span website="full_review"> are untouched, as are the CSS block, footer disclaimer and structural markup. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER source section mapped into the QRS is empty; every source section (Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Therapeutic Protocol, Monitoring Protocol & Defining Success) carries content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | All six Key Interaction labels reproduce the ER bold labels verbatim (lines 573–585); protocol labels “Standard inhalation protocol”, “Best time of day”, “Single versus split dosing” match ER bullets exactly. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Monitoring marker names are verbatim from the ER biomarker table; benefit/risk items reuse the ER headings. Time-to-effect labels are the only derived labels, and the ER supplies no bold labels for them. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; the ER’s “⚠️ Conflicted” marker on the sleep benefit was correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every card is condensed relative to the ER: benefit/risk tiers are single semicolon-separated lines, gate items are stripped of consequence and mitigation clauses, and monitoring targets drop the ER’s “Context/Notes” column entirely. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the descriptive text sits on line 2 before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header, footer or any card. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: bergamot_oil_2026-0825-0244_Opus_ER.md, matching the ER’s own filename frontmatter value. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0817-0547, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname + version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: bergamot_oil_2026-0825-0244_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user and git_issue; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Bergamot Oil for Health & Longevity - Quick Reference Sheet”; matches ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Bergamot Oil for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/17/2026, correctly derived from qrs_creation_date: 2026-0817-0547. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s alternate_names line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all four Conclusion paragraphs: what the oil is and how it is used, the short-term anxiety signal, the thinner mood/sleep/pain/dementia evidence, and the single avoidable hazard. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “Pressed peel oil … Italian citrus fruit” (ER 458), “clearest signal is short-term” (ER 460), “thinner ground” (ER 460), “light-activated … avoidable with care about sun exposure” (ER 462, 464). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “breathing the aroma”, “light-activated skin burns” rather than “inhalation”, “phototoxicity” or “phytophotodermatitis”; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Only the generic “from many small brief studies”; no trial name, year, n or p-value. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect estimate or confidence interval. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six entries map one-to-one to the ER “Populations who should avoid Bergamot Oil” list (ER 308–313) inside that section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-populations present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six discrete <li> elements inside the stop_items span (lines 555–565). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing rationale is stripped, e.g. “where safety data are absent” dropped from the pregnancy item (ER 313 → line 565); no dash-trailing clause anywhere in the gate. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named diseases, the “more than one non-melanoma skin cancer” threshold, Fitzpatrick type I, the named NTI drugs, and the under-6/infant age qualifiers are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify avoid-populations, so the constraint holds. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six entries map to the six ER interaction bullets (ER 294–304). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | The CYP3A4 entry is retained because it covers a broader drug set (simvastatin, apixaban, felodipine) than the narrow-therapeutic-index ingestion contraindication; no entry duplicates a STOP item outright. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Six discrete <li> elements inside the caution_items span (lines 573–585). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s severity word (“Caution.”, “Monitor.”), consequence sentence and “Mitigation:” clause are stripped from every item; only label plus named agents remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs retained throughout, e.g. doxycycline, ciprofloxacin, hydrochlorothiazide, isotretinoin (line 573–575) and lime, bitter orange, grapefruit (line 581). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER lists six interactions, so the constraint holds. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol bullets (ER 335, 343, 347). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose/duration (“Standard inhalation protocol”), timing (“Best time of day”) and frequency structure (“Single versus split dosing”) are the three execution-critical bullets; the remaining ER bullets are attribution, mechanism or subgroup commentary. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated: “3–5 drops, 15 min”, “Pre-stressor or evening”, “Split dosing is the norm”, each with an ER-derived sub-line. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER’s Time to effect bullet (ER 388) supplies exactly three data points — 10–20 minutes for autonomic/anxiety, 1–4 weeks for mood and sleep, and 2 weeks for the postpartum depression trial — and all three are used. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order runs Medium-tier benefit (acute anxiety reduction) first, then the two Low-tier benefits (depressive mood, then sleep), following the ER’s own tier and within-tier ordering. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated: “10–20 minutes”, “2 weeks”, “1–4 weeks”, each with an ER-derived sub-line. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All nine items correspond to the nine ER benefit headings across the Medium, Low and Speculative tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present (lines 530–545). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading, semicolon-separated within its tier; no magnitude figure, p-value or mechanism carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any benefit entry. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High-tier benefit, and benefits_high carries style="display: none" with an empty item (lines 530–532); no empty-state text used. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eight items correspond to the eight ER risk headings across High, Medium, Low and Speculative. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 597–611). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare ER headings only; the Magnitude paragraphs, prevalence figures and IFRA commentary are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(Phytophotodermatitis)” correctly stripped from the High-tier item (ER 228 → line 598); no parentheses remain. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers carry items in the ER, so no sub-section needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows reproduce the ER Monitoring Protocol & Defining Success biomarker table (ER 418–427), including the Optimal Functional Range and Why Measure It columns. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 8 ER biomarkers present in ER order: salivary cortisol, overnight RMSSD, resting blood pressure, resting heart rate, PSQI, STAI state form, photopatch/ROAT, and NTI CYP3A4 substrate trough level. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 731–735 condense the ER’s Baseline and Ongoing paragraphs (ER 414, 416) into one cadence line covering baseline, weekly/monthly ratings, 4-week and 3–6-month re-checks, skin inspection and 6–12-month reassessment. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items reproduce the ER “Qualitative markers worth tracking alongside the numbers” list (ER 431–436). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 6 ER qualitative markers present in ER order, with only terminal full stops removed. |
Issues 17/08/2026 05:55
Pass rate 100.00%. No issues found.
Issues 17/08/2026 05:52
- 9.5 — Example drugs dropped from interaction: The “Photosensitizing prescription drugs” item (QRS lines 573–574) lists only the drug classes and drops the ER’s parenthetical example drugs from ER line 294 — doxycycline, ciprofloxacin, hydrochlorothiazide and isotretinoin.
Fixes 17/08/2026 05:52
- 9.5 — Example drugs restored to interaction: Added the ER’s parenthetical example drugs back to the “Photosensitizing prescription drugs” item — tetracyclines (doxycycline), fluoroquinolones (ciprofloxacin), thiazide diuretics (hydrochlorothiazide), oral retinoids (isotretinoin).